IN2014CN00614A - - Google Patents
Info
- Publication number
- IN2014CN00614A IN2014CN00614A IN614CHN2014A IN2014CN00614A IN 2014CN00614 A IN2014CN00614 A IN 2014CN00614A IN 614CHN2014 A IN614CHN2014 A IN 614CHN2014A IN 2014CN00614 A IN2014CN00614 A IN 2014CN00614A
- Authority
- IN
- India
- Prior art keywords
- human ngf
- antibody
- seq
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011176209 | 2011-08-11 | ||
| JP2011269215 | 2011-12-08 | ||
| PCT/JP2012/070433 WO2013022083A1 (ja) | 2011-08-11 | 2012-08-10 | 新規抗ヒトｎｇｆ抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00614A true IN2014CN00614A (el) | 2015-04-03 |
Family
ID=47668585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN614CHN2014 IN2014CN00614A (el) | 2011-08-11 | 2012-08-10 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8986952B2 (el) |
| EP (1) | EP2743348B1 (el) |
| JP (1) | JP5376095B2 (el) |
| KR (1) | KR101999867B1 (el) |
| CN (1) | CN103748222B (el) |
| AR (1) | AR087506A1 (el) |
| AU (1) | AU2012293161B2 (el) |
| BR (1) | BR112014002576B1 (el) |
| CA (1) | CA2841181C (el) |
| CY (1) | CY1119914T1 (el) |
| DK (1) | DK2743348T3 (el) |
| EA (1) | EA024292B1 (el) |
| ES (1) | ES2663968T3 (el) |
| HR (1) | HRP20180155T1 (el) |
| HU (1) | HUE036079T2 (el) |
| IL (1) | IL230797A (el) |
| IN (1) | IN2014CN00614A (el) |
| LT (1) | LT2743348T (el) |
| ME (1) | ME02944B (el) |
| MX (1) | MX351273B (el) |
| NO (1) | NO2743348T3 (el) |
| PL (1) | PL2743348T3 (el) |
| PT (1) | PT2743348T (el) |
| RS (1) | RS56876B1 (el) |
| SI (1) | SI2743348T1 (el) |
| TW (1) | TWI554519B (el) |
| WO (1) | WO2013022083A1 (el) |
| ZA (1) | ZA201400741B (el) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9783602B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| JP6135161B2 (ja) * | 2013-02-08 | 2017-05-31 | アステラス製薬株式会社 | 新規抗ヒトｎｇｆ抗体 |
| US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
| TWI706959B (zh) * | 2015-05-22 | 2020-10-11 | 日商安斯泰來製藥股份有限公司 | 新穎抗人類ＮＧＦ抗體Ｆａｂ片段 |
| KR20180123559A (ko) * | 2016-03-25 | 2018-11-16 | 아스텔라스세이야쿠 가부시키가이샤 | PEG화 항인간 NGF 항체 Fab' 프래그먼트 함유 의약 조성물 |
| CN109929035B (zh) * | 2017-12-15 | 2022-06-28 | 安源医药科技（上海）有限公司 | 抗人ngf抗体及其制备方法和用途 |
| JPWO2019221097A1 (ja) | 2018-05-15 | 2021-05-27 | アステラス製薬株式会社 | 抗ヒトｎｇｆ抗体又はその抗原結合フラグメントを有効成分とする心房細動の抑制用医薬組成物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0690132B1 (en) * | 1993-03-11 | 2003-12-17 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Anti-hiv monoclonal antibody |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2448956C (en) | 2001-05-30 | 2017-10-03 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| CN102746399B (zh) | 2002-12-24 | 2016-03-02 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| WO2005019266A2 (en) | 2003-07-15 | 2005-03-03 | Amgen Inc. | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| BRPI0606933B8 (pt) | 2005-01-24 | 2021-05-25 | Cambridge Antibody Tech Limited | membro de ligação específico isolado para fator de crescimento de nervos, molécula de anticorpo isolado, composição e uso de um membro de ligação específico |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| KR101709495B1 (ko) | 2007-08-10 | 2017-02-23 | 리제너론 파아마슈티컬스, 인크. | 인간 신경성장인자에 대한 고친화성 인간 항체 |
| SI2206707T1 (sl) | 2007-10-24 | 2014-11-28 | Astellas Pharma Inc. | Azolkarboksamidna spojina ali njena sol |
| EP2448970B1 (en) | 2009-05-04 | 2014-07-09 | Abbott Research B.V. | Antibodies against nerve growth factor (ngf) with enhanced in vivo stability |
-
2012
- 2012-08-10 ME MEP-2018-28A patent/ME02944B/me unknown
- 2012-08-10 ES ES12821758.5T patent/ES2663968T3/es active Active
- 2012-08-10 PT PT128217585T patent/PT2743348T/pt unknown
- 2012-08-10 MX MX2014001627A patent/MX351273B/es active IP Right Grant
- 2012-08-10 JP JP2013525474A patent/JP5376095B2/ja not_active Expired - Fee Related
- 2012-08-10 PL PL12821758T patent/PL2743348T3/pl unknown
- 2012-08-10 EA EA201490433A patent/EA024292B1/ru not_active IP Right Cessation
- 2012-08-10 AU AU2012293161A patent/AU2012293161B2/en not_active Ceased
- 2012-08-10 SI SI201231222T patent/SI2743348T1/en unknown
- 2012-08-10 TW TW101128963A patent/TWI554519B/zh active
- 2012-08-10 IN IN614CHN2014 patent/IN2014CN00614A/en unknown
- 2012-08-10 KR KR1020147003155A patent/KR101999867B1/ko active IP Right Grant
- 2012-08-10 DK DK12821758.5T patent/DK2743348T3/en active
- 2012-08-10 CN CN201280039293.3A patent/CN103748222B/zh not_active Expired - Fee Related
- 2012-08-10 WO PCT/JP2012/070433 patent/WO2013022083A1/ja active Application Filing
- 2012-08-10 NO NO12821758A patent/NO2743348T3/no unknown
- 2012-08-10 LT LTEP12821758.5T patent/LT2743348T/lt unknown
- 2012-08-10 RS RS20180173A patent/RS56876B1/sr unknown
- 2012-08-10 CA CA2841181A patent/CA2841181C/en active Active
- 2012-08-10 US US13/879,267 patent/US8986952B2/en active Active
- 2012-08-10 EP EP12821758.5A patent/EP2743348B1/en active Active
- 2012-08-10 HU HUE12821758A patent/HUE036079T2/hu unknown
- 2012-08-10 AR ARP120102927 patent/AR087506A1/es active IP Right Grant
- 2012-08-10 BR BR112014002576-2A patent/BR112014002576B1/pt not_active IP Right Cessation
-
2014
- 2014-01-30 ZA ZA2014/00741A patent/ZA201400741B/en unknown
- 2014-02-03 IL IL230797A patent/IL230797A/en active IP Right Grant
-
2015
- 2015-01-14 US US14/596,874 patent/US20150218265A1/en not_active Abandoned
-
2018
- 2018-01-26 HR HRP20180155TT patent/HRP20180155T1/hr unknown
- 2018-02-14 CY CY20181100180T patent/CY1119914T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN00614A (el) | ||
| NZ706377A (en) | Il-6 antagonists and uses thereof | |
| NZ603499A (en) | Human cytomegalovirus neutralizing antibodies and uses thereof | |
| NZ703653A (en) | Anti-fap antibodies and methods of use | |
| NZ611468A (en) | Humanized antibodies to liv-1 and use of same to treat cancer | |
| MX357965B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. | |
| NI201200171A (es) | Anticuerpos hacia gdf8 humano | |
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| CY1118551T1 (el) | Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4 | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| EP2532365A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| NZ701444A (en) | Antibodies to matrix metalloproteinase 9 | |
| MX2014001371A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| MY177098A (en) | Novel anti-human tslp receptor antibody | |
| NZ714516A (en) | Human antibodies to clostridium difficile toxins | |
| MY185811A (en) | Novel anti-human tie-2 antibody | |
| MX2012000316A (es) | Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos. | |
| JOP20190103B1 (ar) | شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري | |
| MX2016008520A (es) | Anticuerpo bdca-2 antihumano novedoso. | |
| AU2012315616A8 (en) | Identification of antigen-specific adaptive immune responses using Arm-PCR and high-throughput sequencing | |
| MX2013011414A (es) | Novedoso anticuerpo anti-receptor de il-23 humano. | |
| EA201491240A1 (ru) | Новое антитело против ctgf человека | |
| NZ594452A (en) | Anti-mst1r antibodies and uses thereof | |
| MX2018011039A (es) | Podocalixina y anticuerpos relacionados con tra, metodos de preparacion y usos como agente terapeutico anticancerigeno. | |
| JP2014515743A5 (el) |